Gsk-650394

Gsk-650394

SCHEMBL30753539

O=C(O)c1ccc(-c2c[nH]c3ncc(-c4ccccc4)cc23)cc1C1CCCC1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
CAMKK2 Q96RR4 17/20 1.00
CAMKK1 Q8N5S9 4/20 1.00
SGK1 O00141 3/20 1.00
AURKA O14965 1/20 1.00
SGK3 Q96BR1 1/20 1.00
SGK2 Q9HBY8 1/20 1.00
AXL P30530 4/20 0.67

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Gsk-650394 SCHEMBL29368746 1.00 CAMKK2 (1.00) CAMKK2CAMKK1SGK1AURKASGK3
Gsk-650394 SCHEMBL3767908 1.00 CAMKK2 (1.00) CAMKK2CAMKK1SGK1AURKASGK3
SCHEMBL3767383 0.81 CAMKK2 (1.00) CAMKK2CAMKK1SGK1AURKASGK3
SCHEMBL3768084 0.79 CAMKK2 (1.00) CAMKK2CAMKK1SGK1AURKASGK3
SCHEMBL3767167 0.79 CAMKK2 (0.76) CAMKK2CAMKK1SGK1AURKASGK3
SCHEMBL3762417 0.78 CAMKK2 (0.74) CAMKK2CAMKK1SGK1AURKASGK3
SCHEMBL3764354 0.78 CAMKK2 (0.82) CAMKK2CAMKK1SGK1AURKASGK3
SCHEMBL3766865 0.78 CAMKK2 (1.00) CAMKK2CAMKK1SGK1AURKASGK3
SCHEMBL3774587 0.77 AXL (1.00) CAMKK2SGK1AURKASGK2AXL
SCHEMBL3759420 0.77 AXL (1.00) CAMKK2SGK1AURKASGK2AXL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4662319-A2 PERSONALIZED CRISPR PROFILING FOR CANCER Integrate Bioscience LLC (US) 2025-12-17 EP disclosed
CN-119950724-A Application of SGK1 as marker in tumor immunotherapy 北京大学 2025-05-09 CN disclosed
WO-2024168301-A2 PERSONALIZED CRISPR PROFILING FOR CANCER FUNCTION ONCOLOGY, INC. (US) 2024-08-15 WO disclosed
CN-118021814-A Combination therapy with EHMT2 inhibitors EPIZYME股份有限公司 2024-05-14 CN disclosed
CN-110621316-B Combination therapy with EHMT2 inhibitors EPIZYME股份有限公司 2024-01-26 CN disclosed